Block Listing Interim Review
Updated : 10:21
| 30 May 2018 |
Futura Medical plc
("Futura" or "the Company")
Block Listing Interim Review
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology today makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares.
The table below provides further detail. The figures include the block admission of 1,190,000 ordinary shares on 30 May 2018, as announced on 25 May 2018.
Name of company: | Futura Medical plc |
|
| |||
Name of scheme(s): | Unapproved Share Option Scheme ("USOS") |
|
| |||
Period of return: | From: | 25 November 2017 |
|
| ||
To: | 30 May 2018 |
|
| |||
Number and class of securities not issued under the scheme(s) at beginning of period |
USOS: |
2,396,110 |
|
| ||
EMI: | 2,671,390 |
|
| |||
Total: | 5,067,500
|
|
| |||
Number and class of securities admitted to the scheme(s) in the period | USOS: | 400,000 |
|
| ||
EMI: | 790,000 |
|
| |||
Total: | 1,190,000
|
|
| |||
Number of securities issued under the scheme(s) during the period
Number of securities lapsed under the scheme(s) during the period | USOS: | (150,000) |
|
| ||
EMI:
USOS: EMI:
| (160,000)
(302,145) (457,855)
|
|
| |||
Balance of securities under the scheme(s) not yet issued at the end of the period | USOS: | 2,343,965 |
|
| ||
EMI: | 2,843,535 |
|
| |||
Total: | 5,187,500 |
|
| |||
|
|
|
|
| ||
Number and class of securities originally admitted and the date of admission | USOS: | 814,424 on 25 May 2011, 1,202,280 on 8 October 2013, 1,466,208 on 25 May 2017, 400,000 on 30 May 2018 | ||||
USOS Total: | 3,882,912 |
|
| |||
|
|
|
| |||
EMI: | 1,520,576 on 25 May 2011, 1,467,720 on 8 October 2013, 1,893,792 on 25 May 2017, 790,000 on 30 May 2018 | |||||
EMI Total: | 5,672,088 |
|
| |||
|
|
|
| |||
| Total: | 9,555,000
|
|
| ||
Name of contact: | Angela Hildreth, Finance Director/COO |
|
| |||
Telephone number of contact: | +44 (0) 1483 685 670 |
|
| |||
For further information please contact:
Futura Medical plc |
|
James Barder, Chief Executive | Tel: +44 (0) 1483 685 670 |
Email to: james.barder@futuramedical.com | |
N+1 Singer (Nominated Adviser and Broker) |
|
Aubrey Powell / Liz Yong Corporate Finance
| Tel:+44 (0) 20 7496 3000 |
For media enquiries please contact: |
|
Buchanan |
|
Mark Court / Sophie Cowles / Stephanie Watson | Tel: +44 (0) 20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.